2-[7-fluoro-5-hydroxy-2-(1H-indazol-5-yl)-benzofuran-3-yl]-furan-3-carbonitrile | 1191045-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[7-fluoro-5-hydroxy-2-(1H-indazol-5-yl)-benzofuran-3-yl]-furan-3-carbonitrile
• 英文别名: 2-[7-fluoro-5-hydroxy-2-(1H-indazol-5-yl)-1-benzofuran-3-yl]furan-3-carbonitrile
• CAS: 1191045-95-0
• 化学式: C₂₀H₁₀FN₃O₃
• 分子量: 359.316
• InChiKey: PVHZJEUHXNOGTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] NOVEL ESTROGEN RECEPTOR LIGANDS<br/>[FR] NOUVEAUX LIGANDS DE RÉCEPTEUR DE L'OETROGÈNE
  申请人：KAROBIO AB

  公开号：WO2009124968A1

  公开（公告）日：2009-10-15

  The invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt: wherein R3 is selected from the group consisting of ORA; -CHO; -C(O)C1-4alkyl; -C(O)phenyl; -O-C(O)RA; and N(RB)2; R6 is selected from certain cyclic groups defined in the specification; and the remaining groups are defined in the specification; together with a pharmaceutically acceptable carrier. Most of the compounds are novel. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

  本发明提供了一种药物组合物，包括一种公式(I)的化合物或其药用可接受的酯、酰胺、溶剂化物或盐，包括这种酯或酰胺的盐，以及这种酯、酰胺或盐的溶剂化物：其中R3选自ORA；-CHO；-C(O)C1-4alkyl；-C(O)phenyl；-O-C(O)RA；和N(RB)2；R6选自说明书中定义的某些环状基团；其余基团在说明书中定义；以及药用可接受的载体。大部分化合物是新颖的。本发明还提供了将这种化合物用于治疗或预防与雌激素受体活性相关的疾病或障碍相关状况的方法。
• NOVEL ESTROGEN RECEPTOR LIGANDS
  申请人：Nöteberg Daniel

  公开号：US20110112142A1

  公开（公告）日：2011-05-12

  The invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt: wherein R 3 is selected from the group consisting of OR A ; —CHO; —C(O)C 1-4 alkyl; —C(O)phenyl; —O—C(O)R A ; and N(R B )2; R 6 is selected from certain cyclic groups defined in the specification; and the remaining groups are defined in the specification; together with a pharmaceutically acceptable carrier. Most of the compounds are novel. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

  本发明提供了一种制药组合物，包括式（I）的化合物或其药学上可接受的酯、酰胺、溶剂或盐，包括此类酯或酰胺的盐，以及此类酯、酰胺或盐的溶剂：其中R3选自OR A；—CHO；—C（O）C1-4烷基；—C（O）苯基；—O—C（O）RA；和N（RB）2的基团组成的群体中；R6选自规定在说明书中的某些环状基团；其余基团在说明书中定义；与药学上可接受的载体一起使用。大多数化合物是新的。本发明还提供了在治疗或预防与雌激素受体活性相关的疾病或紊乱相关条件中使用此类化合物的方法。